A multilaboratory in vitro study was 
Quality control parameters are needed to guide clinical microbiology laboratories in the day-to-day performance of disk diffusion antimicrobial agent susceptibility tests. These parameters are guidelines, usually in the form of limits above or below which grouped mean or individual inhibitory zone measurements should not occur. The National Committee for Clinical Laboratory Standards recommended a disk diffusion evaluation method (1) which includes several tables outlining quality control limits for a variety of currently available antimicrobial agents. A recent publication (2) and the critiques of profiency testing programs (College of American Pathologists; Special Bacteriology Survey specimens D-10, D-15, and D-20 of 1979 and D-05 of 1980) have noted problems with currently published ampicillin and carbenicillin inhibitory zone ranges for quality control. As new antimicrobial agents become available for regular clinical use, quality control data frequently lag behind, putting the clinical laboratory in the position of producing information without assurance that the test procedure is in control.
A controlled multilaboratory in vitro study was designed to obtain disk diffusion data in order to reevaluate quality control standards for ampicillin and carbenicillin and to establish preliminary standards for two new semisynthetic penicillins, mezlocillin (Delbay Laboratories) and piperacillin (Lederle Laboratories).
The objective of this study was to establish control limits that would be practical for routine clinical use and still provide a satisfactory level of confidence in test results. Variables that are not subject to rigid control were introduced. Examples of these variables include several lots of Mueller-Hinton agar (MHA) from different manufacturers, three different lots of testing disks from at least two manufacturers, and the involvement of several technologists in nine geographic regions. Tests with ampicillin and E. coli resulted in 20 of 27 instances (74%) in which one or more disks showed significantly different mean inhibitory zones. These differences ranged from 0.4 to 3.8 mm.
On the other hand, when carbenicillin, mezlocillin, and piperacillin were tested with E. coli, there were five, seven, and seven instances, respectively, of significant difference, with corresponding ranges of 0.4 to 0.5 mm, 0.4 to 0.6 mm, and 0.4 to 0.6 mm.
With S. aureus, instances of significantly different mean inhibitory zone diameters with the four antimicrobial agents were observed, as follows: ampicillin, two (range, 0.8 to 1.0 mm); carbenicillin, five (range, 0.6 to 1.2 mm); mezlocillin, four (range, 0.3 to 1.2 mm); and piperacillin, two (range, 0.5 to 0.7 mm).
Only three antimicrobial agents were tested against P. aeruginosa, and again, instances of significant differences in mean inhibitory zone diameters were seen: carbenicillin, seven (range, 0.3 to 0.8 mm); mezlocillin, two (range, 0.4 to 0.6 mm); and piperacillin, 4 (range, 0.5 to 0.9 mm).
Only two antimicrobial agents, ampicillin and carbenicillin, were tested with disks produced by all three manufacturers. There were 36 opportunities for disagreement with ampicillin (P. aeruginosa was not tested) and 54 such opportunities for carbenicillin. The frequency of disagreement among the disks of the three manufacturers was not significant (chi square: 0.795, 2 df; P > 0.20). These disagreements were thus distributed randomly, and no manufacturer was in disagreement more often than any other. Of a possible 90 instances, BBL disks disagreed 26 times with the disks of the other manufactuers; Difco disks disagreed 25 times; and Pfizer disks disagreed 21 times.
In the case of mezlocillin and piperacillin, in which two of the three lots of disks tested were made by a single manufacturer (BBL, mezlocillin; and Difco, piperacillin), none of the laboratories noted significant differences among the mean inhibitory zone diameters when using disks produced by the same manufacturer. The significant differences that were seen (13 of a No.a Range (mm) No." Table 1 reveal that the frequency of significant differences among mean inhibitory zone diameter of the different lots of disks was low, except for ampicillin and E. coli. The occurrences of these differences tended to be distributed randomly among the participating laboratories, and the actual differences observed were, for the most part, less than 1 mm. Since the disks of any one manufacturer had equal opportunities to disagree with the disks of one or both of the other manufacturers, a disparity in the frequency with which these disagreements occurred would indicate a real difference due to manufacturer. This was not observed, lending further weight to the conclusion that no real differences among the performance of disks of different manufacturers were evident. The discrepancies noted with the ampicillin-E. coli test cannot be adequately explained, since these same disks, when tested with S. aureus, gave good agreement in most laboratories. From a practical point of view, the <1-mm disagreement between replicate inhibitory zone diameters demonstrated in most laboratories, although statistically significant in some cases, is probably not important clinically.
Interlaboratory comparisons. Differences in mean inhibitory zone diameters obtained by each laboratory from each antimicrobial agentorganism combination tested on the common lot of MHA were compared by using a one-way analysis of variance test. If significant (P < 0.05) differences between laboratory means were noted, further testing was carried out with the Newman-Keuls multiple-range test to determine which laboratory or laboratories caused the differences. Data obtained with all three lots of disks were combined (Table 2 ). For each antimicrobial agent-organism combination, the laboratories were ranked from largest mean inhibitory zone diameter to smallest. Braces indicate groups of data within which there was no significant variation (P > 0.05), as determined by the Newman-Keuls test. In no instance were the data obtained in each laboratory considered to be statistically representative of a population with the same mean and standard deviation. For example, for mezlocillin and E. coli, means from laboratories D, A, C, and B represent one population, and those from laboratories E, G, H, and F represent another population. Laboratory I remained separate from all the rest. In many instances, ambiguities in assignment to data population groups were present. These are indicated by overlapping braces (see Table 2 ). Means within the overlap (e.g., laboratories D, A, and E; E. coli-carbenicillin combination) could not be assigned with certainty to either population.
There was a tendency for some laboratories to agree with certain other laboratories. For example, laboratories A and D were frequently grouped together. In general, laboratories tending to report larger or smaller inhibitory zones did so with each drug-organism combination.
Quality control parameters, i.e., the upper and lower control limits for individual inhibitory zones, were difficult to determine from the data obtained in this study. The nine laboratories failed to provide a normally distributed body of data which could be subjected to straight-forward parametric statistical analysis. This was true even with the data gathered from the tests which used the common lot of MHA. This disquieting situation no doubt results from the basic design of the study protocol, which purposely attempted to introduce as many of the variables into the testing procedure that would be reasonably expected to be encountered in routine clinical practice. Many technologists set up and standardized inocula, inoculated different lots of MHA, and measured inhibitory zone diameters. Tests were done on different days in various regions of the United States, with possibly different environmental conditions (e.g., the relative humidity in Salt Lake City during this study was <10%). Because of the multiple variables, these data probably represent a close estimate of the current practice in laboratories VOL. 14, 1981 on September 26, 2017 by guest http://jcm.asm.org/ tage of being less affected by extreme (skewed) We therefore recommend the following ap-observations, such as those present in this study. proach to redefining existing quality control pa-The upper and lower control limits were then rameters (e.g., for ampicillin and carbenicillin) established by considering the range of inhibiand determining them for new antimicrobial tory zone diameters obtained in the individual agents (e.g., mezlocillin and piperacillin). We laboratories as a measure of test variability and took the median inhibitory zone diameter for applying ±0.5 the median range (rounded up to the entire population of data for each drug-or-the nearest whole number) to the population ganism combination (Table 3) as the most legit-median. For example, the median range obimate measure of the central tendency. The tained in the nine laboratories when E. coli was median, in contrast to the mean, had the advan-tested with piperacillin was 6 mm. Since the for Clinical Laboratory Standards (1) ( Table 4) . 
